Long-term experience with a preshaped left ventricular pacing lead.
This study describes a long-term experience with a new LV pacing lead. The study population consisted of 62 patients (85% men, 71 +/- 10 years old) with advanced dilated cardiomyopathy, in NYHA Class III or IV despite optimal drug therapy, and a QRS duration > 150 ms. Patients in sinus rhythm were implanted with a triple chamber pacemaker to maintain atrioventricular synchrony. A dual chamber pacemaker was implanted in patients in atrial fibrillation for biventricular pacing only. A clinical evaluation and interrogation of the resynchronization pacemaker were performed at implant, at 1 week (W1), one (M1), four (M4), and seven (M7) months after implantation. A longer follow-up (2 years) is available for patients implanted at the authors institution. LV measurements were pacing threshold at 0.5-ms pulse duration and pacing impedance. R wave amplitude (mV) was measured at the time of implantation only. The system was successfully implanted in 86% of patients with the latest design of the lead. Mean R wave amplitude at implant was 15 +/- 7 mV and mean pacing impedance was 1054 +/- 254 omega. Between implant (n = 38) and M7 (n = 15), pacing threshold rose from 0.73 +/- 0.54 to 1.57 +/- 0.60 V (P < 0.001). In conclusion, the situs lead was successfully implanted in a high percentage of patients. In addition, low pacing threshold and high impedance measured during follow-up are consistent with a low pacing current drain, ensuring a durable pulse generator longevity.
Ollitrault
Jacky
J
Hôpital Européen Georges Pompidou 20, rue Leblanc, 75908 Paris, France. j.ollitrault@free.fr
Ritter
Philippe
P
Mabo
Philippe
P
Garrigue
Stéphane
S
Grossin
François
F
Lavergne
Thomas
T
D000368:Aged; D001281:Atrial Fibrillation / Q000628:therapy; D002304:Cardiac Pacing, Artificial / Q000009:adverse effects / Q000379:methods; D002311:Cardiomyopathy, Dilated / Q000503:physiopathology / Q000628:therapy*; D004562:Electrocardiography; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial / Q000009:adverse effects